Toleranzia AB
0EH
Company Profile
Business description
Toleranzia AB is a Swedish biotechnology Company. The company develops drugs that harness the power of the immune system to treat autoimmune orphan diseases The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease.
Contact
Arvid Wallgrens backe 20
8th floor
GothenburgSE-413 46
SWET: +46 763199898
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
10
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,166.70 | 8.80 | 0.11% |
| CAC 40 | 8,108.59 | 86.26 | 1.08% |
| DAX 40 | 23,109.79 | 257.13 | 1.13% |
| Dow JONES (US) | 42,481.15 | 102.17 | -0.24% |
| FTSE 100 | 8,663.80 | 25.79 | 0.30% |
| HKSE | 23,344.25 | 561.31 | -2.35% |
| NASDAQ | 18,223.49 | 34.90 | 0.19% |
| Nikkei 225 | 37,780.54 | 172.05 | 0.46% |
| NZX 50 Index | 12,184.51 | 56.30 | 0.46% |
| S&P 500 | 5,762.74 | 4.83 | -0.08% |
| S&P/ASX 200 | 7,942.50 | 5.60 | 0.07% |
| SSE Composite Index | 3,369.98 | 0.05 | -0.00% |